GlassScriptPhysician profile
Katherine Farquhar
NPI 1548604424
$2,079.26
in general payments reported to CMS, 2019-2025
18 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $836 · 2024: $785 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $339.47 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $235.07 | 2023-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.48 | 2023-2025 | Lifevest |
| Amgen INC. | $159.54 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $153.49 | 2023-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.81 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $145.81 | 2023-2025 | |
| Chiesi USA, INC. | $137.71 | 2023-2024 | Kengreal, Cleviprex |
| Kiniksa Pharmaceuticals International, Plc | $132.07 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $115.30 | 2023-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $71.92 | 2023-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $46.44 | 2023-2024 | Xarelto |
| Esperion Therapeutics, INC. | $45.42 | 2023-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $42.49 | 2024-2025 | |
| Pfizer INC. | $38.00 | 2023-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.10 | 2025 | Trelegy Ellipta |
| Kiniksa Pharmaceuticals, LTD. | $20.36 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $14.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Farquhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.